Navigation Links
SPO Medical Reports Second Quarter 2008 Results
Date:8/15/2008

Company Maintains Quarterly Revenues in Challenging Marketplace

NEW YORK, August 15 /PRNewswire-FirstCall/ -- SPO Medical Inc. (OTC: SPOM - News), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced its second quarter results for the period ended June 30, 2008.

Gross revenues for the period were US$1,089,000, a 1% increase over first quarter 2008 gross revenues. The Company maintained consistent gross revenue levels despite the challenging worldwide economic environment, particularly in its primary U.S. homecare market.

During the second quarter, the Company released its PulseOx 7500(TM) supporting GUI (graphic user interface) and report generation in multiple languages including French, Italian, German and Spanish ("FIGS") along with English. Additionally, the Company announced it had initiated field trials for its latest homecare wellness product using SPO's patented technology and creating a new application for the traditional home baby monitor market.

Michael Braunold, President and Chief Executive Officer of SPO Medical commented, "Despite a less than favorable macro-economic climate, we continue to introduce new products into the marketplace while expanding the distribution of our existing product line. Last quarter we were excited to announce our foray into the professional healthcare market with the introduction of two new products, the PulseOx 6000(TM) and PulseOx 6100(TM). We are pleased to report during the second quarter we witnessed an increase in sales and distribution for these new products " Mr. Braunold continued, "Additionally, the release of the enhanced PulseOx 7500(TM) supporting FIGS report generation has been received well by our European distributors."

A more detailed description of the financial results and financial statements are contained in the Company's most recent Quarterly Report on Form 10-QSB filed with the SEC.

About SP
'/>"/>

SOURCE SPO Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... DIEGO and HONG KONG ... innovative rare disease therapeutics enterprise, announced today that rare ... the company as vice president, research. Dr. McKew brings ... including key leadership positions at the National Institutes of ... its acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias Biotherapeutics, ... Company has signed a Notice of Grant Award ... (CIRM), effective October 1, 2014.  The NGA provides ... and the release of additional grant funds pursuant ... award for clinical development of Asterias, product, AST-OPC1. ...
(Date:10/20/2014)... PureTech , a science and technology development ... today the closing of a $55 million growth ... a $120 Billion group of funds. The funding ... forward and to advance new healthcare related products ... really go for the big ideas that can ...
(Date:10/19/2014)... The Latin American hardware encryption display market ... with analysis and forecast of revenue. This market was ... to reach $2,366.8 million by 2018, at a CAGR ... the TOC of the Latin American hardware encryption market ... provided. It also provides a glimpse of the segmentation ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3
... 22 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ... of Darmstadt, Germany, has initiated a global Phase 3 ... with hormone receptor-positive, locally advanced, recurrent or metastatic breast ... developed by Merck KGaA under a license agreement with ...
... , , , , SINGAPORE, June 22 ... The EU,s commitment to achieve a reduction in CO2 emissions by ... of a target of 5.75 percent bio-fuels of all transportation fuel ... States is a smaller market, it is witnessing rapid growth in ...
... BioPharma Corp. (TSX, FSE: HBP) today announced that Dr. ... will be presenting a scientific poster describing L-DOS47 analytical ... Pharmaceutical Scientists ("AAPS") National Biotechnology Conference, which runs from ... and Trade Center in Seattle, Washington. , ...
Cached Biology Technology:Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 2Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 3Oncothyreon announces initiation of Phase 3 trial of Stimuvax in breast cancer 4Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 2Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 3Government Mandates Create Guaranteed Market for Bio-Fuel, Says Frost & Sullivan 4Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 2Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 3Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 4Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference 5
(Date:10/16/2014)... infections and worldwide claims the lives of 160,000 ... University have succeeded in developing a promising vaccination ... , Xavier Saelens (VIB/UGent): "We discovered a new ... development of a novel approach to vaccination against ... small children and elderly people." , RSV: ...
(Date:10/15/2014)... Life, is a non-traditional biophysics textbook and it describes ... a journey of discovery into biological systems and provides ... regulation. It is about how our genes make proteins ... billions of cells in an organism. It quantifies the ... which can be found on both large and small ...
(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
Breaking Biology News(10 mins):New perspectives for development of an RSV vaccine 2New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2
... University paleobiologist Gregory M. Erickson sliced up some ... an international team of scientists identify a new ... only subtle similarities, the FSU researcher determined that ... North America's hulking Tyrannosaurus rex. , Make that ...
... the once almost universally fatal childhood cancer acute lymphoblastic ... future, thanks to improvements in diagnosis and treatment over ... Jude Children's Research Hospital. Almost 4,000 cases of ALL ... two-thirds of which are in children and adolescents, making ...
... and Geoff Garnett (of Imperial College London) suggests that ... controlled through antiretroviral drugs alone, even if universal access ... the open-access international medical journal PLoS Medicine, without additional ... about safe sex, access to drugs is likely to ...
Cached Biology News:FSU biologist says new dinosaur is oldest cousin of Tyrannosaurus rex 2FSU biologist says new dinosaur is oldest cousin of Tyrannosaurus rex 3St. Jude projects 90 percent cure rate for ALL 2St. Jude projects 90 percent cure rate for ALL 3St. Jude projects 90 percent cure rate for ALL 4St. Jude projects 90 percent cure rate for ALL 5Access to antiretrovirals unlikely to reduce HIV infection rates 2
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Biology Products: